These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 11717328)

  • 1. Natural compounds show antiangiogenic activity.
    Marwick C
    J Natl Cancer Inst; 2001 Nov; 93(22):1685. PubMed ID: 11717328
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiangiogenic therapy at a crossroads: clinical trial results and future directions.
    Ellis LM
    J Clin Oncol; 2003 Dec; 21(23 Suppl):281s-283s. PubMed ID: 14645411
    [No Abstract]   [Full Text] [Related]  

  • 3. Neovastat--a novel antiangiogenic drug for cancer therapy.
    Gingras D; Boivin D; Deckers C; Gendron S; Barthomeuf C; Béliveau R
    Anticancer Drugs; 2003 Feb; 14(2):91-6. PubMed ID: 12569294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic strategies and agents in clinical trials.
    Rosen L
    Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new cancer blockers.
    Johns Hopkins Med Lett Health After 50; 2004 Oct; 17(8):1-2, 7. PubMed ID: 15602777
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiogenesis. A boost for tumor starvation.
    Marx J
    Science; 2003 Jul; 301(5632):452-4. PubMed ID: 12881543
    [No Abstract]   [Full Text] [Related]  

  • 7. Monitoring responses to antiangiogenic agents using noninvasive imaging tests.
    Libutti SK; Choyke P; Carrasquillo JA; Bacharach S; Neumann RD
    Cancer J Sci Am; 1999; 5(5):252-6. PubMed ID: 10526663
    [No Abstract]   [Full Text] [Related]  

  • 8. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
    Gagne P; Akalu A; Brooks PC
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endostatin: are the 2 years up yet?
    Schellens JH; Ratain MJ
    J Clin Oncol; 2002 Sep; 20(18):3758-60. PubMed ID: 12228194
    [No Abstract]   [Full Text] [Related]  

  • 10. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
    Roukos DH; Tzakos A; Zografos G
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor Angiogenesis: A Key Target for Cancer Therapy.
    Marmé D
    Oncol Res Treat; 2018; 41(4):164. PubMed ID: 29587285
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic targeting of the tumor vasculature.
    Tozer GM; Bicknell R
    Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 14. Anticancer therapy with angiogenesis inhibitors.
    Ghilardi C; Bani MR; Giavazzi R
    Tumori; 2001; 87(6):S14-6. PubMed ID: 11989610
    [No Abstract]   [Full Text] [Related]  

  • 15. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy.
    Mazeron R; Anderson B; Supiot S; Paris F; Deutsch E
    Cancer Treat Rev; 2011 Oct; 37(6):476-86. PubMed ID: 21546163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Closing in on cancer.
    Park A
    Time; 2001 May; 157(20):60, 62. PubMed ID: 11383110
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials.
    Leach MO; Brindle KM; Evelhoch JL; Griffiths JR; Horsman MR; Jackson A; Jayson G; Judson IR; Knopp MV; Maxwell RJ; McIntyre D; Padhani AR; Price P; Rathbone R; Rustin G; Tofts PS; Tozer GM; Vennart W; Waterton JC; Williams SR; Workman P
    Br J Radiol; 2003; 76 Spec No 1():S87-91. PubMed ID: 15456718
    [No Abstract]   [Full Text] [Related]  

  • 18. Rationale, problems and perspectives in anti-angiogenic therapy.
    Lorusso G; Dell'Eva R; Vené R; Pfeffer U; Albini A
    Tumori; 2001; 87(6):S17-9. PubMed ID: 11989611
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel agents target existing tumor vasculature.
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):303. PubMed ID: 20235388
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiangiogenic tumor therapy.
    Davis DW; McConkey DJ; Zhang W; Herbst RS
    Biotechniques; 2003 May; 34(5):1048-50, 1052, 1054 passim. PubMed ID: 12765031
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.